Featured Intelligence

Chronic kidney disease has a structural problem that most serious conditions do not. It is silent through its early stages, the two tests that detect it are cheap and widely available, and for most of the past three decades there

American thyroid cancer diagnoses have more than tripled since the early 1990s. The death rate over the same period has stayed flat. When a disease is found three times as often and kills exactly as many people, the extra diagnoses

Drug resistance is a familiar story when the organism is a bacterium. It gets far less attention when the organism is a fungus, which is unfortunate, because the fungal version of the problem has fewer drugs standing between a patient

After a colon tumour is removed, the central question is whether anything was left behind. For decades the only answers were a pathology report describing how far the tumour had spread and a schedule of scans that would eventually show

In early 2025 the FDA approved suzetrigine, sold as Journavx, for moderate to severe acute pain. It was the first genuinely new mechanism in oral analgesia in roughly a quarter of a century, and it arrived with an unusually clear

For five years, a Medicare waiver has let approved hospitals treat genuinely acute patients in their own homes rather than in a ward: daily clinician visits, remote monitoring, infusions and oxygen delivered to the house, and an inpatient-level payment

Tinnitus, the perception of sound with no external source, affects a large share of adults and has had essentially nothing to offer beyond sound masking and cognitive behavioural therapy. A device that pairs sound delivered through headphones with mild electrical

Prostate cancer screening has spent two decades caught between two bad outcomes. Testing PSA and biopsying everyone with an elevated result finds cancers that would never have caused harm, leading to treatment with real consequences for continence and sexual function.

Biologic medicines, the large protein drugs that treat rheumatoid arthritis, inflammatory bowel disease, psoriasis and many cancers, account for roughly five percent of American prescriptions and about half of total drug spending. Biosimilars are the approved copies meant to bring